Elevance Health Inc ELV

$386.43 +4.76 (1.25%)

Valuation

Market cap
83,804,688,000
Revenue TTM
$199,125,000,000
Net income TTM
$5,662,000,000
PE ratio
12.99
Forward PE
14.03
Profit margin
2.84%
Debt to equity
0.69

Trading

Volume
892,600
Avg volume
1,076,494
Day's range
$380.65 – $388.04
Shares out
216,869,000
Stochastic %K
29%
Beta
0.70
Analysts
Strong Sell
Price target
$449.57

Price

Company profile

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based a...

Show more

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Industry
Healthcare Plans
Sector
Healthcare
Phone
833 401 1577
Website
https://www.elevancehealth.com
Address
220 Virginia Avenue, Indianapolis, United States

Latest news

Stocktwits

Techdamentals Sep 30, 12:27 PM
$ELV If your employer pays $18,000 a year for your coverage and the premium jumps 8%, the inflation number on TV never records it. You didn't pay it. The Fed's number records all of it. That gap is why the two official inflation measures are currently about a point apart. https://techdamentals.com/newsletter/why-pce-is-higher-than-cpi?ref=st
0 replies
AStrokeOfLuck Sep 22, 5:36 PM 2 replies
NVDAMillionaire Sep 22, 10:19 AM
$ELV Excellent article that nails exactly where ELV stands right now. So if you want to update your ELV knowledge or get acquainted with ELV, this is a must read. https://everyticker.com/quote/ELV/analysis/medicaid-trough-and-carelon-pivot-elevance-health-s-margin-reset-offers-asymmetric-risk-reward-nyse-elv
0 replies
lextrading Sep 21, 3:41 PM
$UNH When it dropped to 250, I jumped into $ELV as well. Together, they essentially operate as a duopoly in the healthcare industry. I took a similar approach when $V and $MA dipped during Trump’s credit card interest rate scare. Most recently, I went buy on this pair in the semis industry—there’s nowhere to go but up, especially since I hold both. $SMH
0 replies
DidYouReadThis Sep 21, 3:34 AM
Do you think #insurance #companies might have #increased #earnings in 2027 related to #affordable #wholesale #acquisition #cost at $485 for bevacizumab FDA approved for wet AMD #OTLK? ​$CVS $CI $ELV $UNH Survey question: What’s most likely in your opinion to happen to off label/compounded bevacizumab for wet age related macular degeneration?
1 replies
DidYouReadThis Sep 16, 3:24 PM
#lower #BollingerBand? ​$406 by end of year? $UNH , when a story like $OTLK comes around, (FDA approved ophthalmic bevacizumab for wet AMD… whereas compounded bevacizumab has a …cough… cough…. #popular #history of use in the #eyes) how much of a #lag might you expect for over 50% of #insurance companies to potentially make $OTLK’s a #firststepedit #failfirst #option for wet age related macular degeneration #wetAMD? $ELV $CI
0 replies
StrayTrader Sep 14, 9:21 PM
$UNH $40 lower than $ELV … that won’t last. This will correct back upwards to $400+ at some point soon enough.
1 replies
XCal57 Sep 11, 7:11 PM
$UNH to back up the down next week, $ELV just matched its July 14th peak as well! Gonna be some crazy news next week to hurt healthcare. Would surprise me if Trump doesnt mention health bill!
0 replies